MDT-AP-1261
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 72
- os_event
- false
- age_years
- 5
- sex
- M
- new_clusters
- C3
- umap1_2d
- 5.967842006
- umap2_2d
- 2.267574178
- umap1_3d
- 2.309165071
- umap2_3d
- -3.345935598
- umap3_3d
- -2.234252507
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.230
- HEME_METABOLISM+0.140
- APICAL_JUNCTION+0.120
- WNT_BETA_CATENIN_SIGNALING+0.090
- GLYCOLYSIS+0.060
- HYPOXIA+0.040
- NOTCH_SIGNALING+0.010
- BILE_ACID_METABOLISM-0.010
- SPERMATOGENESIS-0.020
- HEDGEHOG_SIGNALING-0.040
Top 10 suppressed
- MYC_TARGETS_V1-0.450
- ALLOGRAFT_REJECTION-0.380
- E2F_TARGETS-0.370
- COMPLEMENT-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
- OXIDATIVE_PHOSPHORYLATION-0.330
- INFLAMMATORY_RESPONSE-0.320
- KRAS_SIGNALING_UP-0.310
- INTERFERON_GAMMA_RESPONSE-0.290
- COAGULATION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0376 | Med | Medulloblastoma | 0.920 |
| 2 | MDT-AP-1120 | Med | Medulloblastoma | 0.896 |
| 3 | MDT-AP-0578 | Med | Medulloblastoma | 0.884 |
| 4 | MDT-AP-0576 | Med | Medulloblastoma | 0.883 |
| 5 | MDT-AP-1357 | Med | Medulloblastoma | 0.881 |
| 6 | MDT-AP-0830 | Med | Medulloblastoma | 0.859 |
| 7 | MDT-AP-1270 | Med | Medulloblastoma | 0.854 |
| 8 | MDT-AP-1135 | Med | Medulloblastoma | 0.846 |
| 9 | MDT-AP-0038 | Med | Medulloblastoma | 0.844 |
| 10 | s0102877 | — | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.090 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |